Parkinson disease is characterized by the loss of dopaminergic neurons, thus decreasing the system's ability to produce and store dopamine (DA). Such ability is often investigated using 18 F-fluorodopa (FD) positron emission tomography. A commonly used model to investigate the DA synthesis and storage rate is the modified Patlak graphical approach. This approach allows for both plasma and tissue input functions, yielding the respective uptake rate constants K i and K occ . This method requires the presence of an irreversible compartment and the absence of any nontrapped tracer metabolite. In the case of K occ , this last assumption is violated by the presence of the FD metabolite 3-O-methyl-[ 18 F]fluoro-dopa (3OMFD), which makes the K occ evaluation susceptible to a downward bias. It was found that both K i and K occ are influenced by DA loss and thus are not pure measures of DA synthesis and storage. In the case of K occ , the presence of 3OMFD exacerbates the effect of DA egress, thus introducing a disease-dependent bias in the K occ determination. These findings imply that K i and K occ provide different assessments of disease severity and that, as disease progresses, K i and especially K occ become more related to DA storage capacity and less to the DA synthesis rate.
Parkinson disease (PD) affects approximately 300 in 100,000 of the general population (Schoenberg et al., 1988) . Its clinical symptoms include resting tremor, rigidity, bradykinesia, and postural instability leading to increasing motor impairment as the disease progresses. These characteristics are attributed to a progressive loss of the neurotransmitter dopamine (DA) caused by the degeneration of the dopaminergic neurons of the substantia nigra pars compacta that project to the striatum.
The positron emission tomography (PET) tracer 18 Ffluorodopa (FD) has been used extensively to investigate the integrity of the dopaminergic system. 18 F-Fluorodopa is transported across the blood-brain barrier (BBB) via the large neutral amino acids (LNAA) system. It is subsequently decarboxylated via L-aromatic amino acid decarboxylase (AAAD) into 18 F-dopamine (FDA), which is then trapped in the presynaptic vesicles (trapping compartment) and/or further metabolized into L-3,4dihydroxy-6-[ 18 F]fluorophenylacetic acid (FDOPAC) and [ 18 F]6-fluoro-homovanillic acid (FHVA), which are capable of leaving the brain. 18 F-Fluorodopa in plasma and brain is also metabolized by catechol-O-methyltransferase (COMT) into 3-O-methyl-[ 18 F]fluoro-DOPA (3OMFD), which crosses the BBB via the same LNAA system. It is usually assumed that in the healthy state, the accumulation of FDA in synaptic vesicles accounts for most of the striatal radioactivity for the first 90 to 120 minutes after FD administration. F-Fluorodopa kinetics are fairly complex, particularly because of the presence of its metabolites in both plasma and tissue. Models have been developed to isolate the rate constants of the three main distinct processes involved in FD metabolism: transport of FD across the BBB, FD decarboxylation, and the tissue ability to retain FDA and its metabolites Cumming and Gjedde, 1998; Huang et al., 1991) . The statistical quality of the PET data, however, often fails to support the definition of all of the rate constants describing these processes. Thus, a simpler method is commonly used for the analysis of FD uptake, based on the graphical approach developed by Patlak et al. (1983) modified for the case of FD by Martin et al. (1989) . The basic principle of this method is that accumulation of the tracer into an irreversible compartment can be reliably identified even if the intermediate reversible components of the tracer kinetics are not fully identified or known. If steady state between compartments is reached and an irreversible compartment exists, a linear relation is obtained between the ratio of the specific compartment and plasma radioactivity and the ratio between the running integral and the instantaneous value of the plasma radioactivity (often denoted as "stretch time"). The slope of the straight line yields the FD uptake rate constant K i (K i ‫ס‬ K 1 k 3 /(k 2 + k 3 )), where K 1 is the first-order rate constant for transfer of FD from plasma into brain, k 2 the rate constant for the return of free FD from brain back to plasma, and k 3 the rate constant describing the trapping of brain FD by DOPA decarboxylase. Although K i does not provide information about each of the three steps described above separately, it has been always interpreted as a marker of DA synthesis and storage.
The Patlak-based graphical approach has also been extended to include a tissue input function (Patlak and Blasberg, 1985) . The time-activity course of a region devoid of trapping, typically the occipital cortex or the cerebellum, is used as input. In this case, the stretch time corresponds to the ratio between the running integral and the instantaneous value of the reference region, and the slope of the straight line (K occ ) is equal to k 2 k 3 /(k 2 + k 3 ). An added complication with this approach is the presence of 3OMFD in the reference region, which artificially increases the input function and therefore biases the K occ toward smaller values. Nevertheless, this method is very commonly used, because it significantly alleviates the scanning procedure, since no blood samples need to be taken. In addition, K occ has been proven by many investigators to provide a sensitive discrimination between brain uptake in healthy volunteers and patients with PD. Several studies have compared the disease-discriminating ability of K i and K occ (Vingerhoets et al., 1994 (Vingerhoets et al., , 1996 Morrish et al., 1998; Takikawa et al., 1994; Leenders et al., 1990; Hoshi et al., 1993) , with K occ usually found to be the better discriminator. The conventional interpretation of K i and K occ is as markers of DA synthesis and storage. They are evaluated using an irreversible model approach and are thought to be independent of the loss of FDA, represented by the first-order rate constant k loss , which occurs as a consequence of FDA release by the presynaptic vesicles and subsequent metabolism and transport out of the system. It has also been assumed that K i and K occ are equivalent measures of disease progression. In the present study, we investigated the validity and limitations of these assumptions. In particular, we explored a possible dependence of K i and K occ on FDA loss, and we examined the effect of the presence of 3OMFD on the values of K occ . These investigations were performed by examining the K i /K occ ratio as a function of disease severity, by comparison of the disease severity estimations by K i and K occ , and by investigating the empirical results with simulation studies.
MATERIALS AND METHODS

Patient selection, scanning methods and region of interest placement
Three groups of subjects were selected in this study: 6 healthy volunteers, 9 subjects with very early PD (PD1 group), and 11 patients with more advanced PD (PD2 group). Disease duration, defined as time from the onset of symptoms as first noticed by the patient, was 3 years or less (mean duration 2.1 ± 0.8 years, mean ± SD) for PD1 (3 women and 6 men, age 62.9 ± 8.7, mean ± SD). Four of the nine patients were still untreated at the time of the study. Disease duration in PD2 (3 women and 8 men, age 62.2 ± 10.9 years, mean ± SD) was at least 5 years (mean duration 10.9 ± 5.2 years, mean ± SD). The healthy group comprised 2 men and 4 women of similar age (52.2 ± 8.4 years, mean ± SD) to the subjects in the PD1 and PD2 groups. The motor component of the Unified Parkinson's Disease Rating Scale was 11 ± 5 (mean ± SD, range 5 to 18) for PD1 and 30 ± 12 (mean ± SD, range 13 to 51) for PD2. Fifteen patients were taking levodopa/carbidopa (Sinemet; Merck Frosst, Canada), three patients were taking DA agonists, and four were taking antidepressant medication. All medication was stopped at least 12 h before the scan.
Twenty-four of the 26 subjects were part of another study and underwent a 4-h FD scan on a Siemens/CTI ECAT 953B PET tomograph (Siemens/CTI, Knoxville, TN, U.S.A.) (Spinks et al., 1992) operating in three-dimensional mode (Sossi et al., 1998) after injection of 7 mCi of FD (effective dose equivalent 4.2 mSV). All of the subjects received oral administration of 150 mg of the peripheral decarboxylase inhibitor carbidopa 1 h before FD injection. Data were corrected for attenuation using an external 68 Ge source. The scanning sequence consisted of 9 × 10-minute scans, after which the patients could leave the bed for 30 minutes, followed by a final sequence of 12 × 10 minutes for a total of 240 minutes of elapsed time from injection. The repositioning was aided by use of a thermoplastic mask, which also helped to minimize head motion during the scan. Images from the first and second scanning sequences were coregistered using the AIR algorithm (Woods et al., 1993) . Four 61-mm 2 circular regions of interest (ROIs) were placed on each side of the striatum: one on the caudate nucleus and three on the putamen [anterior (P1), middle (P2), and posterior putamen (P3)]. Six 270-mm 2 circular ROIs were placed on the occipital cortex in the five adjacent planes containing the striatum. All regions were applied to each frame of the dynamic sequence to generate the corresponding time-activity curves (TACs).
Thirty-seven arterial blood samples were taken to obtain the plasma radioactivity time course. Twelve were analyzed for metabolites to identify the FD and the 3OMFD plasma fractions. The metabolite separation was performed as previously described with an alumina extraction method with anion/cation exchange columns (McLellan et al., 1991; Doudet et al., 1998) . With this method, the cation column captures the positively charged metabolites (FD and 6-fluoro-3-methoxytyramine) and the anion column the negatively charged metabolites FDOPAC and FHVA and sulfated conjugates. 18 F-Fluorodopa and 3OMFD, both unretained by the columns, are then separated by alumina extraction.
The remaining two subjects underwent an identical scanning and data analysis protocol, with the exceptions that they were injected with 5 mCi of FD and scanning and blood sampling were stopped at 90 minutes after tracer administration. All studies received the approval of the University of British Columbia Ethics Committee. Informed consent was obtained from all subjects.
Estimations of K i , K occ , and K i /K occ K i and K occ were determined using the Patlak graphical approach (Patlak et al., 1983; Patlak and Blasberg, 1985) described in the Introduction. The radioactivity in the specific compartment (trapped FDA) was obtained from the radioactivity determined in an ROI placed on the striatum after subtraction of the radioactivity present in an ROI placed on the occipital cortex (Martin et al., 1989) . This subtraction eliminates the contribution of the 3OMFD from the radioactivity in the striatal ROI . When the tissue input function is used, there is a further residual influence of 3OMFD; the radioactivity values measured in the reference region contain an indistinguishable contribution from 3OMFD.
In the absence of 3OMFD, the ratio between K i and K occ is by definition equal to the distribution volume K 1 /k 2 , if all model assumptions are satisfied for the entire time-course. It has been shown that the K 1 /k 2 value does not change as a function of disease (Kuwabara et al., 1995) . It has also been shown that the metabolism of FD to 3OMFD is disease independent (Chan et al., 1991) . When 3OMFD is present, the K i /K occ ratio is expected to increase because of the bias in K occ . If no disease-dependent bias is introduced by the analysis methods, and if the irreversibility assumptions (see Introduction) are satisfied, this ratio should be the same in all three groupshealthy, PD1, and PD2. The following analyses were performed to investigate the consistency of the methods: K i and K occ were calculated for the caudate and putamen separately for the time spans 0 to 70 and 0 to 90 minutes after injection. K i /K occ ratios were calculated in each case. K i , K occ and the K i /K occ ratio were compared among the three groups for the caudate and putamen separately for each time span.
Disease severity
If all the model assumptions are satisfied and the K i /K occ ratio is indeed proportional to K 1 /k 2 , K i and K occ should be equivalent estimators for the deterioration of the dopaminergic system and thus of disease severity or progression. Disease severity was defined as the values of K i and K occ in the disease groups PD1 and PD2 relative to those in the healthy group (PD1/N and PD2/N) and was estimated for caudate and putamen separately for each time span.
Simulations
To investigate the effect of k loss on the determination of K i and K occ and their ratio, and a disease-dependent effect of 3OMFD on K occ , a method that used a combination of simulation and measured data was developed. Compartmental analysis was applied to the average putaminal TACs (obtained by averaging the TAC of the six ROIs placed on the putamen) and average occipital cortex TACs (obtained by averaging the TAC of the six ROIs placed on the occipital cortex) for a randomly chosen subset of the healthy group (five subjects) and a subset of the PD2 group (seven subjects). The measured FD and 3OMFD input functions were used together with the model described in Fig. 1 . The data included in the fitting procedure spanned all 4 h of the scanning protocol. First the occipital cortex data TACs were fitted with four free parameters: K 1 Ј, k 2 Ј, K 1m Ј, and k 2m Ј, where K 1 Ј and k 2 Ј are the first-order rate constants describing the transfer from plasma into tissue and the reverse for FD, K 1m Ј and k 2m Ј are the corresponding parameters for 3OMFD, and the prime symbol indicates rate constants evaluated for the reference region. Because the putaminal TACs do not support the determination of every individual rate constant, the fit was then performed with K 1m and k 2m constrained to equal K 1m Ј and k 2m Ј and three remaining free parameters: K 1 , k 2 , and k 3 . Because a reliable value for k loss could not be obtained from the data, possibly because of the lack of fine temporal sampling of the PET data immediately after tracer injection, its values were constrained to two test pairs: 0.001 for the healthy group and 0.003 for the PD2 group, and 0.002 for the healthy group and 0.004 for the PD2 group (Huang et al., 1991) . Two test sets were used to reflect the range of values existing in the literature and those obtained in our DA turnover studies (Sossi et al., 2002) .
Once the values of the parameters were obtained, nearly noiseless TACs for the putaminal and occipital cortical regions FIG. 1. 18 F-Fluorodopa (FD) kinetics in the striatum. 18 F-Fluorodopa is transported across the blood-brain barrier (BBB) via the large neutral amino acid (LNAA) system. It is subsequently decarboxylated by L-aromatic amino acid decarboxylase (AAAD) into [ 18 F]fluorodopamine (FDA), which is then trapped in the presynaptic vesicles and/or further metabolized into L-3,4-dihydroxy-6-[ 18 F]fluorophenylacetic acid (FDOPAC) and [ 18 F]6-fluorohomovanillic acid (FHVA), which are capable of leaving the brain. 18 F-Fluorodopa in plasma and brain is also metabolized by catechol-O-methyl-transferase (COMT) into 3-O-methyl-[ 18 F]fluoro-DOPA (3OMFD), which crosses the BBB via the same LNAA system. The amount of FD O-methylation in brain is generally considered negligible. 18 F-Fluorodopa kinetics in the reference region are considered identical except for the lack of the FD conversion into FDA.
were formed using the model equations and the measured plasma FD and 3OMFD TACs. The first 90 minutes of these TACs together with the measured FD input function were then used to calculate the model values for K i and K occ , K i-mod and K occ-mod . K i-mod and K occ-mod were compared with the measured K i and K occ for each subject to ensure that the fitted values for the rate constants were in a reasonable range. Be-cause the scanning protocol did not include very fine PET time sampling, a direct comparison of the individual parameter values to those obtained in the literature was not appropriate. The purpose of this fitting procedure was not to find highly accurate individual parameters values but to obtain estimates realistic enough to yield the experimental uptake rate constant values. By subsequently setting the appropriate individual parameters to zero and recalculating K i and K occ , an estimate of the impact of the individual components on K i and K occ was obtained.
When thus validated, K i-mod and K occ-mod were recalculated for each subject under the following conditions: (1) k loss ‫ס‬ 0;
(2) K 1m ‫ס‬ 0; and (3) k loss ‫ס‬ K 1m ‫ס‬ 0. Conditions 1 and 2 showed the separate effects of k loss and 3OMFD on K i and K occ , whereas condition 3 explored the effects of possible interactions between the uncorrected presence of 3OMFD and k loss . Table 1 shows the group average values of K i , K occ , and the corresponding disease severity estimates for the two time spans. The value of K i does not change as a function of time interval for any group. It exhibits the typical rostrocaudal gradient for the PD group. The value for K occ calculated over 70 minutes is larger than K occ calculated over 90 minutes for all three groups. This is indicative of a curvature in the tissue input Patlak plot shown in Fig. 2 (see Results-simulations) . It is interesting to note that a curvature is present even in the data obtained for the healthy group as observed by Hoshi et al. (1993) . 
RESULTS
Effect of scan duration on K i and K occ and disease severity estimates
Group Normal 0.0189 ± 0.0026 0.0189 ± 0.0024 0.0119 ± 0.0011 0.0138 ± 0.0011 0.0180 ± 0.0019 0.0181 ± 0.0017 0.0107 ± 0.0009 0.0122 ± 0.0009 PD1 0.0152 ± 0.0038 0.0151 ± 0.0041 0.0097 ± 0.0011 0.0111 ± 0.0014 0.0110 ± 0.0042 0.0111 ± 0.0043 0.0058 ± 0.0019 0.0065 ± 0.0020 PD2 0.0134 ± 0.0035 0.0130 ± 0.0029 0.0079 ± 0.0011 0.0087 ± 0.0010 0.0082 ± 0.0027 0.0086 ± 0.0026 0.0036 ± 0.0009 0. 
FIG. 2. Example of a plasma input (A) and a tissue input (B)
Patlak plot for a healthy subject. In the case of the plasma input, the "stretch time" contains the running integral of the plasma 18 F-fluorodopa time-activity curves (TACs), whereas in the case of the tissue input the stretch time contains the running integral of the occipital cortex TAC. The asterisks are the measured data, whereas the solid line is the line obtained from the fit. The slope of the line is K i (A) and K occ (B). A curvature is observable in the data used to determine K occ . The effect of disease severity on the magnitude of K occ exceeds the effect on K i , and the amount of discrepancy between the assessment obtained with K i and K occ increases as a function of disease severity. Thus, the discrepancy is very small for the caudate of the PD1 group but becomes progressively larger for the caudate of the PD2 group, the putamen of the PD1 group, and, finally, the putamen of the PD2 group, thus following the expected topologic pattern of disease progression.
K i /K occ ratios
The K i /K occ ratios averaged over the subjects of each group are shown in Table 2 . Very similar results were obtained for both time spans: there is no difference in the ratio between the healthy group and PD1 for the caudate. The ratio is higher for the PD2, but these increases did not reach statistical significance. For the putamen, a borderline significant difference in the ratio was found between the PD1 and PD2 (P ‫ס‬ 0.05, two-sided t-test for the 90-minute data and P ‫ס‬ 0.07 for the 70-minute data) and a highly significant difference between the healthy and PD2 groups (P < 0.005, two-sided t-test for both the 70-and 90-minute data). No significant difference was found between the healthy and PD1 putamen K i /K occ ratios (P ‫ס‬ 0.24, two-sided t-test for the 90-minute data and P ‫ס‬ 0.14 for the 70-minute data), but a very significant difference was found when the comparison was made between the healthy and the PD1 and PD2 groups taken together (P < 0.005, two-sided t-test for both time spans).
These results, together with the discrepant assessment of disease severity by K i and K occ , indicate that the two uptake rate constants must be differentially sensitive to some other effect in addition to being markers of DA synthesis and storage. As previously mentioned, FDA loss and 3OMFD were identified as possible candidates to explain the discrepancy.
Simulations Table 3 shows the K i-mod , K occ-mod , ratio mod (K i-mod /K occ-mod ) together with the actual measured values for putaminal TACs for the 12 subjects included in the simulation study. Data presented here were obtained The two columns on the right show the ratio between K i-mod and K occ-mod with various parameters set to zero and their values obtained when all parameters (a.p.) were included in the simulation. Here, k loss was set to 0.002 for the normal (N) group and to 0.004 for the Parkinson disease (PD2) group. by setting k loss to 0.002 for the healthy group and to 0.004 for PD2. There is very good agreement between the measured and simulated parameter values. The Pearson correlation coefficient r between the model and measured values was 0.99 for K i , 0.99 for K occ , and 0.9 for the ratio. Figure 3 shows an example of the fit obtained from the model. Although an accurate determination of the individual rate constant was beyond the scope of this study (see Materials and Methods) , the values obtained were in general agreement with published values (Cumming and Gjedde, 1998) . The mean ± SD value of k 3 was 0.021 ± 0.008 in the healthy group and 0.010 ± 0.005 for PD2. The mean FD DV (DV ‫ס‬ K 1 Ј/k 2 Ј) in the cortical region was 1.03 ± 0.35, the mean 3OMFD DV was 1.27 ± 0.20, and the mean FD DV in the striatal region was 1.89 ± 0.85. The latter value was somewhat higher than published values ; this could reflect several factors, including the type of constraints imposed on the individual rate constants and the lack of fine time sampling in the PET scan in the early minutes of the scan. Table 4 shows the K i-mod , K occ-mod , and ratio mod values for the four conditions evaluated: (1) all parameters as defined from the fit; (2) k loss ‫ס‬ 0; 3. K 1m ‫ס‬ 0; and (4) k loss ‫ס‬ K 1m ‫ס‬ 0. Figure 4 shows characteristic examples of the simulated Patlak plots obtained for each condition for both the tissue input and the plasma input methods. It can be seen that most of the curvature in the tissue input Patlak plot is because of the presence of 3OMFD.
Comparison of the model ratio values. A statistically significant difference was found between the ratio values of the two groups (ratio mod in Table 4 ) when the fitted TACs were used to calculate K i-mod and K occ-mod (P ‫ס‬ 0.0087, two-sided t-test), in agreement with the measured data. When FDA loss was set to zero (k loss ‫ס‬ 0), the difference in the ratio values between the two groups was reduced, but it was still statistically significant (P ‫ס‬ 0.033, two-sided t-test). When 3OMFD was absent (K 1m was set to zero), there was no statistically significant difference in the ratio values between the two < FIG. 4. Patlak plots obtained from simulated and measured data. (A) Plasma input function. Asterisks are measured data, and the solid line through the points is the best linear fit to the data, yielding K i . The dashed line almost superimposed on the solid line represents the simulated Patlak data with all parameters included. The corresponding solid line is a fit to the simulated data, yielding K i-mod . The agreement between the measured and simulated Patlak plot is excellent. The upper dashed line represents the simulated Patlak data with k loss = 0, and the upper solid line is the corresponding fit. The absence of k loss manifests itself as an increase in slope. Setting K 1m to 0 does not have any effect on the simulated Patlak data. (B) Tissue input function. Asterisks are measured data, and the solid line through the points is the best linear fit to the data, yielding K occ . The dashed line almost superimposed on this solid line represents the simulated Patlak data with all parameters included. The corresponding solid line is a fit to the simulated data, yielding K occ-mod . The agreement between the measured and simulated Patlak plot is excellent. The upper dashed line represents the simulated Patlak data with k loss = 0, and the upper solid line is the corresponding fit. (C) Tissue input function. The lower dashed curve represents the simulated Patlak data when K 1m = 0, with the solid line being the corresponding fit, whereas the upper dashed curve represents the simulated Patlak data when k loss = K 1m = 0. Note the change in the x-and y-axis scale values. Note also that the curvature present in the data shown in B essentially disappears when K 1m = 0. groups (P ‫ס‬ 0.34, two-sided t-test). Likewise, there was no statistically significant difference between the ratio values in the two groups when both k loss and K 1m were set to zero (P ‫ס‬ 0.39, double-sided t-test).
Effect of k loss on K i and K occ values. The comparison of the K i-mod and K occ-mod values obtained with all parameters and the case where k loss was set to zero shows that k loss influences both K i and K occ . In the healthy group, the effect is only marginally greater for K occ compared with K i (1.14 vs. 1.11, P ‫ס‬ 0.14, two-sided t-test), whereas for the PD2 group the effect is significantly larger for K occ compared with K i (1.38 vs. 1.22, P ‫ס‬ 0.002, two-sided t-test). These results lead to three important observations. First, even in the normal case K i and K occ are influenced by the loss rate and are thus not pure measures of DA synthesis and storage, but also of storage capacity. Second, the effect of k loss increases as a function of disease severity, so that as disease progresses K i and K occ become progressively more related to storage capacity as opposed to DA synthesis rate and storage. Finally, as disease progresses, k loss affects K occ more severely than K i .
Interaction between the effect of k loss and 3OMFD. When K 1m ‫ס‬ 0, the effect of k loss becomes similar for K i and K occ , as indicated by the fact that ratio mod becomes the same for the healthy group and PD2. This is further confirmed by the observation that ratio mod remains unchanged when k loss and K 1m are both set to zero. k loss thus has a greater effect on K occ compared with K i only because of the presence of 3OMFD. The presence of 3OMFD in the tissue input function thus amplifies the effects of disease on the underestimation of K occ .
Disease severity estimation. The effect of disease severity is estimated by the PD2/N ratio in Table 5 . When all parameters are included in the simulation, K i-mod and K occ-mod give a nearly significantly different estimate of disease severity (PD2/N ‫ס‬ 0.46 for K i and 0.35 for K occ , P ‫ס‬ 0.061, two-sided t-test), approaching the results obtained with measured data presented in Table 3 (0.45 for K i and 0.31 for K occ , P < 0.01, two-sided t-test). When k loss is set to zero, the PD2/N ratio increases, still indicating a trend toward a different disease assessment (0.51 for K i and 0.43 for K occ, P ‫ס‬ 0.23, two-sided t-test). When K 1m is set to zero, K i-mod and K occ-mod yield comparable estimates of disease severity (0.46 for K i and 0.44 for K occ ). This still holds when k loss and K 1m are both set to zero; in this case, however, the assessed disease severity is less (0.50). This last case is most closely related to a pure measure of DA synthesis and storage.
The conclusions obtained with the simulation performed by setting k loss ‫ס‬ 0.001 for the healthy group and k loss ‫ס‬ 0.003 for the PD2 group were very similar to those described previously and are summarized in Table  6 . The k loss values considered fall in the lower limit of the published k loss value range. A higher k loss value would further confirm these conclusions.
DISCUSSION
Two important conclusions can be derived from this study: K i and even more so K occ are not pure measures of DA synthesis and storage but are sensitive to DA loss even when they are calculated using only the first 90 minutes of data after tracer injection. The second conclusion is that 3OMFD introduces a disease-dependent bias in the K occ estimate because of the interaction between the effect of k loss and 3OMFD in the input function. The two columns on the right show the ratio between K i-mod and K occ-mod with various parameters set to zero and their values obtained when all parameters (a.p.) were included in the simulation. Here, k loss was set to 0.001 for the normal (N) group and to 0.03 for the Parkinson disease (PD2) group.
The first finding is in apparent contradiction with the assumption that FD behaves as an irreversibly trapped tracer for the first 90 minutes after tracer injection and is therefore suitable for a Patlak graphical analysis. A close examination, however, of the K i Patlak plots obtained in the simulation study (Fig. 4) shows that, during the first 90 minutes after tracer injection, the presence of k loss manifests itself as a reduction of the slope values; its effects are thus indistinguishable from those of a decrease in the trapping rate k 3 . It is also reasonable to assume that the influence of k loss manifests itself even earlier than 90 minutes after tracer injection. No difference was found in the K i values estimated from 70 or 90 minutes of the acquired data. Only in very advanced disease is a curvature in the data during the first 90 minutes observed (unpublished data), and in that case a reduction of the time span over which the K i is calculated might produce more accurate results. Such an approach would, however, introduce some degree of arbitrariness in the analysis method, since the final time point for analysis would have to be determined on a case-bycase basis.
The 3OMFD-based amplification of the k loss effect on K occ arises because the presence of 3OMFD introduces an additional downward curvature in the data (Figs. 2 and 4) due to the inaccurate determination of the true input function from the occipital cortex. In this case, the stretch time contains a time-dependent component related to 3OMFD, which is absent in the value plotted in the y-axis, thus decreasing the correlation between the two axes. This disease-amplifying bias might explain why K occ has in many cases been found to be the most sensitive marker for disease and the best disease progression discriminator (Vingerhoets et al., 1994; Morrish et al., 1998) .
The fact that both K i and K occ are sensitive to k loss implies that to some extent they are also measures of storage capacity or turnover time, especially in advanced stages of disease, when the loss rate is higher (Doudet et al., 1998) . In these extreme cases, when a clear curvature is apparent even in the K i Patlak plots (data not shown), it becomes questionable whether the Patlak analysis can still be applied, because a deviation from a straight-line relation is itself indicative of a certain degree of reversibility. Certainly, at least in these cases, the interpretation of K i and K occ must be revisited. This consideration would lead to an intriguing interpretation of situations where a change in K i or K occ is observed after an intervention such as cell transplant, which is generally performed on patients with very severe disease: does an increase in K i or K occ calculated over the first 90 minutes of data really reflect an increase in DA synthesis, thereby implying that the transplanted cells are capable of DA synthesis, or is it mostly indicative of an increase in storage capacity because of the ability of the transplanted cells to store DA, but not necessarily produce it? More studies are required to investigate this issue.
CONCLUSIONS
The Patlak graphical method is often used to quantify the FDA synthesis and storage rate K i or K occ using the plasma or the tissue input function respectively. Results shown in this study suggest that both uptake rate constants are influenced by the FDA release by the presynaptic vesicles and subsequent metabolism and transport out of the system and are thus not pure estimates of DA synthesis. Furthermore, the presence of 3OMFD in the tissue input function introduces a disease-dependent bias in the effect of k loss on K occ . Consequently different quantitative assessments of disease progression or severity are obtained from K i and K occ . Care must thus be taken when relating the meaning of K occ and K i to specific processes and when quantifying changes in disease state, especially in situations of advanced disease.
